Clinical trials: Diabetes Mellitus ( Type 1 and Type 2)
Diabetes Mellitus, Type 1
AT278 and NovoRapid® in Glucose Clamp Study
A phase 1, randomised, single-centre, double-blind, single-dose, two period balanced cross over study in a glucose clamp setting.
- Trial name
- NCT04660305
- Testing
- AT278, NovoRapid
- Where
- Austria
- Volunteers
- 38 people
- Sponsor
- Arecor Limited
Diabetes, Diabetes Mellitus, Type 1
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492218
- Testing
- biphasic human insulin 30
- Where
- Philippines
- Volunteers
- 1,330 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus
Primary Objectives: To determine the effect of insulin glulisine on glycemic control (HbA1c, FBG \& PPBG) from baseline to the end of the study.
- Trial name
- SCALE (NCT00526513)
- Testing
- Insulin Glulisine
- Where
- Egypt
- Volunteers
- 188 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of biphasic insulin aspart 30 in post-marketing use.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01536613
- Testing
- biphasic insulin aspart 30
- Where
- South Korea
- Volunteers
- 5,346 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04937319 following single escalating oral doses in adult subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT01044537
- Testing
- PF-04937319
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pfizer
Essential Hypertension, Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-3" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06636877
- Testing
- BR1019, BR1019-2, BR1019-3
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes, Diabetes Mellitus, Type 1
Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)
This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Obstructive Pulmonary Disease
- Trial name
- iINHALE 8 (NCT00472953)
- Testing
- inhaled human insulin, insulin aspart
- Where
- 27 sites in Argentina, India and 5 more
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
To Evaluate the Efficacy and Safety of the Insulin Patch Pump System in Patients With Diabetes.
Patients will be enrolled and randomly assigned to either the test group or the control group for short-time intensive insulin therapy in inpatient setting.
- Trial name
- NCT07403565
- Testing
- Insulin Patch Pump System, Minimed 700
- Where
- 5 sites in China
- Volunteers
- 161 people
- Sponsor
- Suzhou Hechun Medical Technology Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00617565
- Testing
- biphasic insulin aspart, biphasic human insulin
- Where
- 6 sites in China
- Volunteers
- 219 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes
This study is conducted globally. The aim of this study is to describe the proportion of patients with hypoglycaemic episodes and estimate the incidence of various types of hypoglycaemia in the retrospective and prospective…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02306681
- Testing
- No treatment given
- Where
- 8 sites in Bangladesh, Colombia and 6 more
- Volunteers
- 7,315 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor
The goal of this early first in man clinical trial is to evaluate the safety of an implantable continuous blood glucose monitoring system in participants with Diabetes Mellitus.
- Trial name
- NCT06764069
- Testing
- Sensor Lead
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Glucotrack
Diabetes, Diabetes Mellitus, Type 1
Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate the effectiveness of Tresiba® (insulin degludec) after switching basal insulin in a population with type 1 or type 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- EU-TREAT (NCT02662114)
- Testing
- No treatment given
- Where
- 7 sites in Austria, Denmark and 4 more
- Volunteers
- 2,302 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
Closed Loop Glucose Control in a Simulated ICU Setting
This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Stress Induced Hyperglycemia
- Trial name
- NCT07646067
- Testing
- FUSION closed loop glucose control system
- Volunteers
- 6 people
- Sponsor
- Ideal Medical Technologies
Type 1 Diabetes
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
- Trial name
- VC01-103 (NCT04678557)
- Testing
- VC-01 Combination Product
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- ViaCyte
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction
This study is conducted in Europe. The aim of this study is to assess the well-being of patients following treatment with insulin detemir (Levemir®) in subjects with type 1 or type 2 diabetes in whom either initiation of or a…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- CONFIDENCE (NCT01542476)
- Testing
- insulin detemir
- Where
- Netherlands
- Volunteers
- 299 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Primary objective To determine whether oral ladarixin versus placebo adjunctive therapy improves glycemic control in overweight, insulin resistant (IR) adult subjects with type 1 diabetes (T1D).
- Trial name
- CONSERVA (NCT05368402)
- Testing
- Ladarixin
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Clinical Evaluation of BD NEXT Pen Needle
This prospective, multi-center, 2 period cross-over study is designed to determine if people who use injection pens for subcutaneous medication delivery prefer the BD NEXT pen needle (PN) in comparison with currently marketed pen…
- Trial name
- NCT01852136
- Testing
- BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle, BD NEXT 32G x 4mm pen needle
- Where
- 5 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.
German Multi-centered, randomized, crossover study in diabetic patients evaluating two infusion sets under real life conditions at home.
- Trial name
- NCT02103595
- Testing
- Accu-Chek FlexLink, Accu-Chek FlexLink Plus
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche